Separation Systems for Commercial Biotechnology

Aug 2013| BIO011F| BCC Publishing

Report Highlights

The global market for commercial biotechnology separation systems reached nearly $16 billion in 2012 and is expected to reach $17.1 billion by the end of 2013. The market is expected to grow at a compound annual growth rate (CAGR) of 10.1%, reaching a value of $27.8 billion by 2018.

Report Includes

  • An overview of the global market for the commercial applications of biotechnology separation systems by product, by company, and by geographic region.
  • Analyses of global market trends, with data from 2008 to 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Examination of the various segments of the market, new applications for separation technology, and overall industry trends, as well as the separation process for a variety of biomolecules, including proteins, RNA, and DNA.
  • Identification of one of the major drivers for the separations system market: the development by the biomedical and pharmaceutical industries of proteins that can be used as biotherapeutic agents against a number of human diseases; another factor that will contribute to growth is the recognition of this technology in emerging markets such as Japan and the Pacific Rim countries.
  • Assessments of trends based on a number of parameters, including projected sales for existing products, new product introductions, and expanded indications for existing products.

Report Scope

Current and projected protein and biomolecule separation revenue forecasts during the forecast period (i.e., 2013 to 2018) are discussed. Protein separation systems are playing important roles in new biopharmaceutical development. Protein separation systems do not require U.S. Food and Drug Administration (FDA) approval, but the products produced from these processes do, and they must be produced in accordance with FDA good manufacturing practices (GMP) guidelines. Thus, these separation procedures and equipment must pass FDA audits of the manufacturing process. New products requiring separation technologies that have been approved by the FDA in 2011 and 2012 are covered, and those products expected to be approved within the forecast period are discussed. Due to the timing of the writing of this report, the figures for 2013 are estimated except where actual results have been reported.

The report includes analysis of the leading competitors, as well as emerging companies in the current global biomolecule separation market. Profiles of the manufacturers of the leading products are analyzed, and their specific product strategies are outlined. This report notes companies that are poised to introduce new products during the forecast period and discusses how these products may change the face of the competitive environment. This competitive environment is examined with a special focus on the ways in which developing products and technologies are influencing the current standard of patient care. Detailed profiles of the current market leaders and emerging companies are discussed in detail.

Market figures are based on revenues at the manufacturers’ level. The base year for analysis and projection is 2013. Trends are assessed based on a number of parameters, including projected sales for existing products, new product introductions and expanded indications for existing products.

This report also includes overviews and forecasts of the separations market by product, by company and by geographic region through 2018. The global market is analyzed, and data are provided for each segment.

When considering flow cytometry values, the numbers cited and projected do not include clinical applications, as clinical applications have been defined as falling outside the biotechnology scope of this report.

Sales figures are reported in U.S. dollars and reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data are presented on a global basis unless specifically noted.

Frequently Asked Questions (FAQs)

Analyst Credentials

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Title/Chapter NamePagesMember Price
Full Report: Separation Systems for Commercial Biotechnology121Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY3Free
Chapter- 3: OVERVIEW41Free
Chapter- 9: C. CRAMER & CO. GMBH17Free
Chapter- 11: APPENDIX2Free
Published - Sep-2011| Analyst - Jackson Highsmith| Code - BIO011E

Report Highlights

The global market for commercial biotechnology separation systems reached $12.1 billion in 2010, $14.6 billion in 2011, and it will further grow to $26.7 billion at an estimated compound annual growth rate (CAGR) of 12.8% by 2016.

Published - Feb-2007| Analyst - Alpita Shah| Code - BIO011D

Report Highlights

  • The U.S. market for protein separation systems is estimated to be valued at almost $3.0 billion in the base year, 2006. This market is expected to grow with an average annual growth rate (AAGR) of 11.1% and cross the $5.0 billion by the year 2011.
  • The liquid chromatography market was $944 million in 2004 and will rise to more than $1.1 billion in the year 2006. This market has been showing exceptional growth due to its ability to separate large molecules before major analysis. This market is expected to reach $2.1 billion by 2011, an AAGR of 13.0%.
  • The membrane filtration segment is valued at $538 million in year 2006 with an estimated growth of 10.8% and is predicted to grow to $898 million in year 2011. Though the capital costs involved in membrane filtration are higher than chemical treatments, the system increases energy and utilizes less company space as compared to chemical processes. This enables companies to reduce costs by upwards of 65%.

Published - Nov-2003| Analyst - Norma Corbitt| Code - BIO011C

Report Highlights

  • Biotech separations is a $2.1 billion in the U.S. in 2003 and is projected to rise to $3.6 billion in 2008, at an average annual rate (AAGR) of 11.0%.
  • Fast runs, high throughput and reproducibility are factors in liquid chromatography’s dominance. Rising at an AAGR of 11.3%, this segment will increase to $1.69 billion in 2008.
  • Competition from membrane technologies should continue to limit growth of centrifugation to an AAGR of 6.0% through 2008
  • Readily met sanitary design regulations, easily enclosed systems and greater recovery rates contribute to an AAGR of 14.1% for membrane filtration. Sales should reach $673 million in 2008.
  • Electrophoresis systems, led by capillary designs, will rise at an AAGR of 8.3% from $249 million in 2003 to $371 million in 2008.

Market Research Report

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries